-
Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials
•
U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an antiviral drug for respiratory syncytial virus (RSV), following challenges including drug-drug interactions with antacids. The drug had reached the Phase II/III trial stage, and the decision will see two trials discontinued, according to Endpoints News.…
-
Blue Shield Pharma Faces Bankruptcy Proceedings After Missing Debt Payments
•
The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield Pharma, a China-based pharmaceutical company specializing in tumor drug development. The move comes after Blue Shield Pharma failed to meet its debt obligations. As of April 9, 2024, the company’s total employee debt stood at…
-
LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend
•
LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down its operations following a strategic review in light of challenging biotech market conditions. This decision initiates a gradual process that includes the divestiture of remaining pipeline assets, delisting from NASDAQ, and deregistration as a corporate…
-
LianBio Board Turns Down Concentra Biosciences Buyout Offer
•
China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not to proceed with a buyout proposal from Concentra Biosciences LLC, deeming the offer not to be in the best interests of shareholders. In early December, Concentra Biosciences LLC, a company under the control of private…
-
Concentra Biosciences Targets China-Based Biotech LianBio in Unsolicited Takeover Bid
•
LianBio (OTCMKTS: LIANY), a China-based biotech firm, has become the target of an unsolicited takeover bid by Concentra Biosciences LLC, a company controlled by private equity fund Tang Capital Partners LP. The cash offer is set at USD 4.30 per share for 100% of LianBio’s equity, a significant premium that…
